It is no secret that the PD-(L)1 class of products has become a dominant force in oncology, and despite the proximity to its loss of exclusivity (LoE), it continues to grow and evolve.
In the first of a new series of CRA Insights on this topic, Aaron Everitt looks at how Keytruda and other branded and biosimilar manufacturers are preparing for the upcoming patent expirations. Further, the article also explores new PD-(L)1 inhibitors that are continuing to appear across the globe in 2025 and beyond.
Read more about Keytruda and PD-(L)1 LoE here.
